This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Dec 12;347(24):1982-4; author reply 1982-4.

doi: 10.1056/NEJM200212123472418.

Inflammatory bowel disease

Jaime García de Tena, Luis Manzano Espinosa, Melchor Alvarez-Mon

PMID: 12477955
DOI: 10.1056/NEJM200212123472418

Comment

Inflammatory bowel disease

Jaime García de Tena et al. N Engl J Med. 2002.

. 2002 Dec 12;347(24):1982-4; author reply 1982-4.

doi: 10.1056/NEJM200212123472418.

Authors

Jaime García de Tena, Luis Manzano Espinosa, Melchor Alvarez-Mon

PMID: 12477955
DOI: 10.1056/NEJM200212123472418

No abstract available

PubMed Disclaimer

Comment on

Inflammatory bowel disease.
Podolsky DK. Podolsky DK. N Engl J Med. 2002 Aug 8;347(6):417-29. doi: 10.1056/NEJMra020831. N Engl J Med. 2002. PMID: 12167685 Review. No abstract available.

Similar articles

Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H, Okazaki K, Tabata Y, Chiba T. Nakase H, et al. J Gastroenterol. 2003 Mar;38 Suppl 15:59-62. J Gastroenterol. 2003. PMID: 12698874 Review.
Germ therapy with IL-10 to treat inflammatory bowel diseases.
Michie C. Michie C. Mol Med Today. 2000 Nov;6(11):416. doi: 10.1016/s1357-4310(00)01829-3. Mol Med Today. 2000. PMID: 11074364 No abstract available.
Clinical development of interleukin-10.
Lebeaut A, Garaud JJ. Lebeaut A, et al. Eur Cytokine Netw. 1997 Sep;8(3):303-4. Eur Cytokine Netw. 1997. PMID: 9346368 Review. No abstract available.
Interleukin-10. Cytokine synthesis inhibitory factor, SCH 52000, rIL-10, rhIL-10.
[No authors listed] [No authors listed] Drugs R D. 1999 Mar;1(3):262-4. doi: 10.2165/00126839-199901030-00017. Drugs R D. 1999. PMID: 10566041 No abstract available.
Interleukin 2 targeted therapy in inflammatory bowel disease.
Yarkoni S, Sagiv Y, Kaminitz A, Askenasy N. Yarkoni S, et al. Gut. 2009 Dec;58(12):1705-6. doi: 10.1136/gut.2008.175182. Gut. 2009. PMID: 19923351 No abstract available.

See all similar articles

Cited by

T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis.
Wang L, Ray A, Jiang X, Wang JY, Basu S, Liu X, Qian T, He R, Dittel BN, Chu Y. Wang L, et al. Mucosal Immunol. 2015 Nov;8(6):1297-312. doi: 10.1038/mi.2015.20. Epub 2015 Mar 25. Mucosal Immunol. 2015. PMID: 25807185 Free PMC article.
Distinctive pattern of cytokine production and adhesion molecule expression in peripheral blood memory CD4+ T cells from patients with active Crohn's disease.
García de Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M. García de Tena J, et al. J Clin Immunol. 2006 May;26(3):233-42. doi: 10.1007/s10875-006-9016-4. Epub 2006 May 2. J Clin Immunol. 2006. PMID: 16783463
Salvianolic Acid B Restored Impaired Barrier Function via Downregulation of MLCK by microRNA-1 in Rat Colitis Model.
Xiong Y, Wang J, Chu H, Chen D, Guo H. Xiong Y, et al. Front Pharmacol. 2016 May 26;7:134. doi: 10.3389/fphar.2016.00134. eCollection 2016. Front Pharmacol. 2016. PMID: 27303297 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.